|Bid||0.00 x 900|
|Ask||0.00 x 4000|
|Day's Range||7.86 - 8.15|
|52 Week Range||6.97 - 24.00|
|Beta (3Y Monthly)||3.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.13|
Viking Therapeutics (VKTX) stock closed at $7.98 on June 12, 2.70% higher than its previous close, 14.49% above its 52-week low of $6.97, and 66.75% below its 52-week high of $24.
This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.
SAN DIEGO , May 28, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
We can judge whether Viking Therapeutics, Inc. (NASDAQ:VKTX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best […]
Viking Therapeutics, Inc. (VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). While details of the trial have yet to finalized, we do anticipate the trial including biopsy-confirmed NASH patients with F2 and F3 fibrosis (although there are likely to be a small number with F1 fibrosis). Regarding the upcoming trial, based on the length for competitors Phase 2b trials we estimate that if started in the second half of 2019 topline data would probably be available in the first half of 2021, although 4Q20 isn’t out of the question.
Conference call scheduled for 4:30 p.m. ET today - New Data from Phase 2 Study of VK2809 Presented at EASL 2019; Results Demonstrate Robust Efficacy at Doses as Low as 5 mg Daily - Phase 2b Study of VK2809 ...
Conference Call Scheduled for Thursday, May 2 at 4:30 p.m. Eastern Time SAN DIEGO , April 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
What Are Analysts Recommending for VKTX and ENTA?(Continued from Prior Part)Growth drivers In November 2018, Viking Therapeutics (VKTX) issued a press release announcing positive results from its Phase 2 trial evaluating the efficacy of the 1-mg dose
What Are Analysts Recommending for VKTX and ENTA?Stock price movementOn April 12, Viking Therapeutics (VKTX) closed at $9.35, 6.22% lower than its previous closing price, 153.39% higher than its 52-week low of $3.69, and 61.04% below its 52-week
In addition, all nine patients in the 5 mg cohort experienced ≥ 30% reduction in liver fat and 77.8% were ‘super-responders’, defined as experiencing ≥ 50% reduction in liver fat. For those who may argue that the two patient populations are too dissimilar to offer a valid comparison, we believe that the very similar placebo responses seen in both outcomes in the table below indicate that the two populations are in fact quite similar.
Patients Receiving 5 mg Daily Doses of VK2809 Demonstrated Statistically Significant Median Reduction in Liver Fat Content of 53.8% 88% of Patients Receiving VK2809 Experienced ≥ 30% Reduction in Liver ...
Late-Breaker Presentation to Highlight Efficacy, Safety and Tolerability Results from 12-Week Phase 2 Trial Including New Data from Study's 5 mg Treatment Arm SAN DIEGO , April 4, 2019 /PRNewswire/ -- Viking ...
Every day this week the indices have opened on an upbeat note and then sold off. If you are interested in trading it the best approach is to wait at least 30 minutes to an hour after it opens and watch for a trading range to develop. The trading range provides a mechanism for risk control and nothing more.